Sisomicin Sulfate Injection

Sisomicin sulfate.

It is suitable for the following infections caused by Gram-negative bacilli (including Pseudomonas aeruginosa), Staphylococcus and other sensitive bacteria: respiratory system infections, urogenital system infections, biliary tract infections, skin and soft tissue infections, infectious diarrhea and sepsis, etc. When used for the above-mentioned serious infections, it is advisable to use it in combination with penicillin or cephalosporin.

Intramuscular injection or intravenous drip. 1. Patients with normal renal function: Adults with mild infection: 0.1g per day; severe infection: 0.15g per day. The dosage is divided into 2 to 3 times. Children are given 2 to 3 mg/kg per day according to body weight, divided into 2 to 3 times. The course of treatment is no more than 7 to 10 days. Blood drug concentration should be monitored if conditions permit. 2. Patients with impaired renal function: When patients with impaired renal function use this product, the dosage should be adjusted according to renal function. If conditions permit, blood drug concentration should be monitored at the same time to adjust the dosage.

1. Common symptoms include hearing loss, tinnitus or fullness in the ears (ototoxicity), hematuria, proteinuria, tubular urine, significantly reduced urination frequency or urine volume, loss of appetite, extreme thirst (nephrotoxicity), unsteady gait, dizziness (ototoxicity, vestibular effects), nausea or vomiting (ototoxicity, vestibular effects, nephrotoxicity). 2. Rare symptoms include vision loss (optic neuritis), dyspnea, drowsiness, extreme weakness (neuromuscular blockade), allergic reactions such as rash, changes in blood count, changes in liver function, digestive tract reactions, pain at the injection site, nodules, phlebitis, etc. 3. Very rare anaphylactic shock.

1. It is contraindicated for those who are allergic to this product or other aminoglycosides and bacitracin, or for those who have or have family members who have developed deafness or other hearing loss due to the use of streptomycin. 2. It is contraindicated for those with renal failure.

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4. This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5. This product should not be used in combination with other nephrotoxic or ototoxic drugs or applied sequentially to avoid aggravating nephrotoxicity or ototoxicity. 6. This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline (all of the above are injections) because of incompatibility. 7. This product can often achieve synergistic effects when used in combination with beta-lactams (cephalosporins or penicillins). 8. This product can be mixed with beta-lactams (cephalosporins or penicillins) to cause mutual inactivation. When used in combination, it must be dripped in separate bottles.

Keep tightly closed in a cool, dark place.

1ml: 50,000 units

Tentative 36 months

Suzhou Pharmaceutical Factory

• Founded in:

  2006-02-14

• Address:

  No. 2-1, Dongwu South Road, Wuzhong District, Suzhou City

• Tax NO.:

  91320506138170408U

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view